

# Press Release

**ProStrakan Group plc**

**Pre-Close Trading Update**

**ProStrakan Reports Continued Progress**

**Galashiels, UK. 7 January 2010:** ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today issues a pre-close trading update for the 12 months ended 31 December 2009, prior to presenting at the J. P. Morgan Healthcare Conference on 14 January 2010 and ahead of the publication of the Group's Preliminary Results, scheduled for 18 March, 2010.

## **Key Points**

- Continued strong revenue growth – reiterating guidance of 2009 total revenues in the range £78m - £79m, up by approximately 40% versus 2008 and in line with management's expectations
- EU business grew very strongly in 2009:
  - Abstral achieved excellent sales of £5m - £6m, having been launched during the year in the UK, Germany, France and Spain
  - Pan-European products (Tostran, Rectogesic and Xomolix) recorded sales growth of approximately 30% in 2009
  - Adcal-D3 grew by over 15% in 2009, exceeding £20m for the full year
- Sancuso maintained the sales trajectory reported in the Group's IMS (17 November 2009) delivering revenues of £7m - £8m in 2009
- Continued transition towards profitability with several EBITDA-positive months in 2009
- The ProStrakan Board continues to anticipate strong revenue growth during 2010, and operating profitability for full year 2010

Commenting on today's update, Dr Wilson Totten, Chief Executive of ProStrakan, said:

“2009 has clearly demonstrated the strength of ProStrakan's diversified business model built on a portfolio of high growth products commercialised across a number of key markets. Our European business continues to perform particularly well, with above-expectations performance from Abstral and other EU products.

“With two US approvals expected during the coming 12 months and a further US refiling planned by the middle of 2010, ProStrakan is well-placed to record another year of strong progress as we plan for our first year of operating profitability.”

**Ends**

**For further enquiries, please contact:**

<b>ProStrakan</b>	+44 (0) 1896 664000
Dr Wilson Totten, Chief Executive	
Allan Watson, Chief Financial Officer	
Callum Spreng, Corporate Communications	
<b>Brunswick Group</b>	+44 (0) 20 7404 5959
Jon Coles / Justine McIlroy	

**About ProStrakan:**

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

[www.prostrakan.com](http://www.prostrakan.com)